The living-history museum in Fishers is making plans for a larger exhibit that is expected to open in 2029 and better tell ...

Instead, history repeated itself ... Obvious industry leaders include Intuitive Surgical and Eli Lilly. Lilly returned 32% last year, while Intuitive returned 55%. Another way to play the sector ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro ... it has mastered the art of making its products unforgettable. As marketing consultants at the New England Consulting ...

Google Deepmind co-founder Demis Hassabis talks to FT editor Roula Khalaf about the real world healthcare applications of AI and how his ground-breaking work on the structure of proteins could acceler ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

Eli Lilly and Company (NYSE ... The company has an extended history of paying stable dividends. The annual payment during the last 10 years was $1.96 in 2015, and the most recent fiscal year ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,020.00. Akash Tewari’s rating is based ...